Tandem Diabetes Care (TNDM) News Today

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) stock has moved on mixed analyst actions and company updates. Recent disappointing Q2 results and lowered price targets have weighed on shares, while some longer‐term outlook upgrades and strategic initiatives provide offsetting support.

• Positive Sentiment: Leerink Partners raised its FY2028 EPS estimate for TNDM from $0.42 to $0.53, reflecting improved longer‐term profitability expectations.Leerink Partners Report
• Positive Sentiment: Analyst Mike Kratky of Leerink Partners reaffirmed a Buy rating on TNDM amid growth catalysts, even as he trimmed his price target to $32.00 from $38.00.TipRanks Article
• Positive Sentiment: Tandem projects $1 billion in sales for 2025, driven by international expansion, pharmacy channel growth and product innovation.MSN Article
• Positive Sentiment: Barclays maintained its Overweight rating on TNDM, lowering its price target modestly to $51, implying significant upside from current levels.Benzinga
• Neutral Sentiment: UBS Group trimmed its price target on TNDM to $17 and assigned a Neutral rating, reflecting balanced near‐term prospects.Benzinga
• Neutral Sentiment: Tandem’s FY2025 guidance update reiterated revenue targets around $1 billion, in line with consensus estimates.
• Negative Sentiment: Tandem shares gapped down after reporting Q2 results below expectations, with deeper losses and lower guidance dragging the stock.MarketBeat Article
• Negative Sentiment: Royal Bank of Canada cut its TNDM price target to $25 from $45, though it retained an Outperform rating, signaling lowered near‐term expectations.MarketBeat Article
• Negative Sentiment: Wells Fargo lowered its price objective on TNDM to $13 from $20 and placed the stock at Equal Weight, highlighting caution on near‐term performance.MarketBeat Article
• Negative Sentiment: Piper Sandler downgraded TNDM, adding to mixed analyst views and pressuring the stock.MSN Article
• Negative Sentiment: A voluntary device correction was issued for certain t:slim X2 insulin pumps due to a speaker malfunction that can disrupt glucose monitoring, raising safety concerns.Reuters Article
• Negative Sentiment: TNDM hit a new 52‐week low amid broader sector weakness and investor caution.MarketBeat Article